Sekar Kathiresan (Verve)

'Tremen­dous' an­i­mal da­ta in­spire GV, ARCH's $63M boost­er for Sekar Kathire­san's dri­ve to rel­e­gate coro­nary heart dis­ease to his­to­ry

In the year since Sekar Kathire­san drew the cur­tain on Verve Ther­a­peu­tics and its goal to end the chron­ic care ap­proach to coro­nary heart dis­ease, the aca­d­e­m­ic-turned-CEO has quadru­pled his team and ac­crued what he calls “tremen­dous da­ta” — in­clud­ing a glimpse at how its gene edit­ing med­i­cine might work in non-hu­man pri­mates in vi­vo.

Just ex­act­ly what that means will on­ly be re­vealed to the world at a con­fer­ence lat­er this month. But the in­vestors who had an in­side view are hap­py enough to pony up an­oth­er $63 mil­lion to get the start­up through to first-in-hu­man stud­ies.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.